Xeris Biopharma Holdings Inc (NASDAQ: XERS) on Friday, plunged -3.53% from the previous trading day, before settling in for the closing price of $3.40. Within the past 52 weeks, XERS’s price has moved between $1.69 and $3.87.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 195.35% over the past five years. The company achieved an average annual earnings per share of 20.54%. With a float of $141.35 million, this company’s outstanding shares have now reached $149.00 million.
Let’s look at the performance matrix of the company that is accounted for 377 employees. In terms of profitability, gross margin is 77.02%, operating margin of -24.11%, and the pretax margin is -35.02%.
Xeris Biopharma Holdings Inc (XERS) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Xeris Biopharma Holdings Inc is 5.18%, while institutional ownership is 43.59%. The most recent insider transaction that took place on Aug 12 ’24, was worth 10,147. In this transaction Director of this company bought 4,515 shares at a rate of $2.25, taking the stock ownership to the 25,200 shares. Before that another transaction happened on Aug 09 ’24, when Company’s Director bought 4,285 for $2.37, making the entire transaction worth $10,134. This insider now owns 20,685 shares in total.
Xeris Biopharma Holdings Inc (XERS) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 20.54% per share during the next fiscal year.
Xeris Biopharma Holdings Inc (NASDAQ: XERS) Trading Performance Indicators
Xeris Biopharma Holdings Inc (XERS) is currently performing well based on its current performance indicators. A quick ratio of 1.29 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.52.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.44, a number that is poised to hit -0.07 in the next quarter and is forecasted to reach -0.19 in one year’s time.
Technical Analysis of Xeris Biopharma Holdings Inc (XERS)
Xeris Biopharma Holdings Inc (NASDAQ: XERS) saw its 5-day average volume 1.66 million, a negative change from its year-to-date volume of 1.73 million. As of the previous 9 days, the stock’s Stochastic %D was 20.41%. Additionally, its Average True Range was 0.17.
During the past 100 days, Xeris Biopharma Holdings Inc’s (XERS) raw stochastic average was set at 66.76%, which indicates a significant increase from 28.05% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 56.98% in the past 14 days, which was higher than the 50.35% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.19, while its 200-day Moving Average is $2.53. Nevertheless, the first resistance level for the watch stands at $3.41 in the near term. At $3.53, the stock is likely to face the second major resistance level. The third major resistance level sits at $3.61. If the price goes on to break the first support level at $3.21, it is likely to go to the next support level at $3.13. Assuming the price breaks the second support level, the third support level stands at $3.01.
Xeris Biopharma Holdings Inc (NASDAQ: XERS) Key Stats
Market capitalization of the company is 471.73 million based on 149,081K outstanding shares. Right now, sales total 163,910 K and income totals -62,260 K. The company made 54,270 K in profit during its latest quarter, and -15,740 K in sales during its previous quarter.
